Physician

Internal Medicine

Daniel Everitt practices Internal Medicine. He researched medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Daniel Everitt has written publications. He has 14 publications published with PubMed. The lastest publication is: 'Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure.'

Publications

---

• Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
• An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
• A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
• Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure.
• The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.
• Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.
• Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
• Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension.
• The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.
• Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for sev...
• A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
• A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administratio...
• A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaq...

Schools

---

• Harvard Medical School

• Massachusetts General Hospital

Doctors Specialties

---

• Geriatric Medicine
• Internal Medicine

Accepted Insurances

---

Education

---

• Massachusetts General Hospital
• Harvard Medical School

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

Dr. Gemma G. Rozmus, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog